These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1059 related articles for article (PubMed ID: 28102030)

  • 21. [EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES].
    Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):472-9. PubMed ID: 26638450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empagliflozin: A Review in Type 2 Diabetes.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1037-1048. PubMed ID: 29946963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.
    Dandona P; Chaudhuri A
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28440009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
    Scheen AJ
    Diabetes Res Clin Pract; 2016 Nov; 121():204-214. PubMed ID: 27744129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
    Nauck MA
    Drug Des Devel Ther; 2014; 8():1335-80. PubMed ID: 25246775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Cardiol; 2017 Jul; 120(1S):S59-S67. PubMed ID: 28606346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials.
    Wanner C; Iliev H; Duarte N; Schueler E; Soares AR; Thanam V; Pfarr E
    Adv Ther; 2024 Jul; 41(7):2826-2844. PubMed ID: 38771475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
    Vivian E
    Diabetes Educ; 2015 Dec; 41(1 Suppl):5S-18S. PubMed ID: 26450220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
    Handelsman Y
    Endocr Pract; 2015 Sep; 21(9):1054-65. PubMed ID: 26132997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
    Kim GW; Chung SH
    Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SGLT2 Inhibitors: Benefit/Risk Balance.
    Scheen AJ
    Curr Diab Rep; 2016 Oct; 16(10):92. PubMed ID: 27541294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The SGLT2 inhibitor empagliflozin: results of EMPA-REG OUTCOMER trial].
    Okamura T; Koiwai K
    Nihon Yakurigaku Zasshi; 2016; 148(5):282. PubMed ID: 27803444
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview ofits Chemistry, Pharmacology, and Toxicology.
    Yadav J; Ahsan F; Panda P; Mahmood T; Ansari VA; Shamim A
    Curr Diabetes Rev; 2024; 20(10):e230124226010. PubMed ID: 38265382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
    Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.